secwatch / observer
8-K filed June 14, 2024, 7:59 PM ET ticker RGEN CIK 0000730272
leadership confidence high sentiment neutral materiality 0.75

Repligen appoints Olivier Loeillot as CEO effective Sept 1, 2024; Hunt becomes Executive Chair

REPLIGEN CORP

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Tony J. Hunt

Executive Chair
RGEN · REPLIGEN CORP
Effective
2024-09-01
Successor
Olivier Loeillot
Filed
June 14, 2024, 7:59 PM ET
Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors
Appointed

Olivier Loeillot

President and Chief Executive Officer
RGEN · REPLIGEN CORP
Effective
2024-09-01
Filed
June 14, 2024, 7:59 PM ET
Repligen has appointed Olivier Loeillot, Repligen’s President and Chief Commercial Officer, to the role of President and Chief Executive Officer, as successor to Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors (the “Board”), with such transition to be effective September 1, 2024
Role change

Karen A. Dawes

Lead Independent Director
RGEN · REPLIGEN CORP
Effective
2024-09-01
Filed
June 14, 2024, 7:59 PM ET
appointed Karen A. Dawes, the Board’s current Chair, to the role of Lead Independent Director
Appointed

Olivier Loeillot

Member of the Board
RGEN · REPLIGEN CORP
Effective
2024-09-01
Filed
June 14, 2024, 7:59 PM ET
the Board elected Mr. Loeillot as a member of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tony J. Hunt changed role as Executive Chair at REPLIGEN CORP.

Action
will serve as
Role
Executive Chair
Exact text from the filing
Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Olivier Loeillot was appointed as President and Chief Executive Officer at REPLIGEN CORP.

Action
appointed
Role
President and Chief Executive Officer
Exact text from the filing
Repligen has appointed Olivier Loeillot, Repligen’s President and Chief Commercial Officer, to the role of President and Chief Executive Officer, as successor to Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors (the “Board”), with such transition to be effective September 1, 2024
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Karen A. Dawes was appointed as Lead Independent Director at REPLIGEN CORP.

Action
appointed
Role
Lead Independent Director
Exact text from the filing
appointed Karen A. Dawes, the Board’s current Chair, to the role of Lead Independent Director
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Olivier Loeillot was elected as Member of the Board at REPLIGEN CORP.

Action
elected
Role
Member of the Board
Exact text from the filing
the Board elected Mr. Loeillot as a member of the Board
View on SEC.gov

REPLIGEN CORP filing history →

Source: SEC EDGAR
accession 0001193125-24-161728
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.